COMMUNIQUÉS West-GlobeNewswire

UroGen to Present at March 2018 Investor Conferences

07/03/2018 - 14:00

RA’ANANA, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ: URGN ) today announced that management plans to present at two investor conferences in March 2018: Cowen & Company 38 th [...]

Insmed to Present at the Cowen and Company 38th Annual Health Care Conference

07/03/2018 - 14:00

BRIDGEWATER, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that a member of [...]

Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference

07/03/2018 - 14:00

SOUTH SAN FRANCISCO, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]

Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update

07/03/2018 - 14:00

SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report [...]

Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR

07/03/2018 - 14:00

BILLERICA, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS ), a medical technology company that offers joint replacement implants designed and manufactured to fit and conform to each patient’s [...]

Millennium Blockchain Invests $5 Million in BurstIQ

07/03/2018 - 14:00

SANTA MONICA, CA, March 07, 2018 (GLOBE NEWSWIRE) -- Millennium Blockchain Inc. (OTC: MBLC ), a holding company focused on blockchain technologies and crypto-assets in financial markets, healthcare, crypto-mining and [...]

Chimerix to Present at Cowen and Company 38th Annual Health Care Conference

07/03/2018 - 14:00

DURHAM, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX ), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. [...]

Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

07/03/2018 - 14:00

Ureagenesis normalized in one patient and further increased by 24 weeks Cohort 2 patient enrollment to begin in March 2018; data expected in second half of 2018 NOVATO, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- [...]

WishBone Medical, Inc. and Hospital for Special Surgery (HSS) Collaborate to Develop a Novel Pediatric Total Hip Implant.

07/03/2018 - 14:00

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a new global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants, entered into a license agreement with [...]

Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories

07/03/2018 - 14:00

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has entered into a [...]

Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, 2018, Tuesday at 8:40 AM ET

07/03/2018 - 13:32

RALEIGH, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT ), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory [...]

Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference

07/03/2018 - 13:30

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30 th Annual ROTH [...]

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

07/03/2018 - 13:30

EXTON, Pa. and CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA ), a clinical-stage biopharmaceutical company focused on the discovery, development and [...]

Pacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel System

07/03/2018 - 13:30

MENLO PARK, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB ), the leader in long-read, high-resolution sequencing, today announced a new version of Sequel ® Software (V5 [...]

Summit Expands Enrolment in Phase 2 Clinical Trial to Include Planned Additional Group

07/03/2018 - 13:01

Summit Therapeutics plc ("Summit" or the "Company") Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group Additional Group is Open to Patients Who Participated in Phase 1 [...]

Allergy Therapeutics: Interim Results for the six months ended 31 December 2017

07/03/2018 - 13:00

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0930 GMT today. Dial-in details [...]

Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group

07/03/2018 - 13:00

Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of Ezutromid Allows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD, United Kingdom, March [...]

BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15

07/03/2018 - 13:00

RALEIGH, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI ), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that [...]

Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)

07/03/2018 - 13:00

ANAVEX®2-73 Extends Survival and Reduces Seizures in an Orphan Disease Model NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL ), a clinical-stage [...]